Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression

Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression

Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1, which alone shows a clinical benefit to ~15% of S...

Full description

Bibliographic Details
Main Authors: Philip Vitorino, Chen-Hua Chuang, Alexandre Iannello, Xi Zhao, Wade Anderson, Ronald Ferrando, Zhaomei Zhang, Shravanthi Madhavan, Holger Karsunky, Laura R. Saunders
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
Antibody drug conjugates
Immunogenic cell death
Rovalpituzumab tesirine
Checkpoint inhibitor
PD1
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320303752

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320303752

Similar Items